Licensing Protein Expression Protein Production 
Drug Target Review
APRIL 5, 2024
Together, these attributes provide a strong foundation for protein expression with enough adaptability to produce much of the commercial and therapeutic protein market. They’re prepared for complexity Successful expression of the gene of interest is not sufficient on its own for large-scale production.
The Pharma Data
JANUARY 13, 2021
Germany-based Cevec Pharmaceuticals GmbH signed a licensing agreement with Biogen for the use of its proprietary ELEVECTA Technology for the manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications. The deal will provide Biogen the rights to use the technology across their portfolio of gene therapy products.
Expert insights. Personalized for you.
96 
Let's personalize your content